Asset Details
Do you wish to reserve the book?
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab
Do you wish to request the book?
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab
2024
Overview
Background and Objective:
Our objective was to monitor variables via spectral-domain optical coherence tomography (SD-OCT) and identify the most relevant biomarkers related to best-corrected visual acuity (BCVA) in radiation retinopathy (RR).
Patients and Methods:
A post-hoc analysis of the two-year Ranibizumab for Radiation Retinopathy (RRR) trial analyzed vision and OCT parameters including intraretinal fluid, ellipsoid zone (EZ) disruption, retinal pigment epithelium atrophy, hard exudates, retinal hemorrhage, retinal neovascularization, and subfoveal fluid. BCVA and SD-OCT parameters were evaluated by univariate analysis and a mixed-effects model.
Results:
Forty eyes from the RRR trial were included. Intraretinal cyst vertical size (week 24: P = 0.032; week 48: P = 0.021), neovascularization (week 48: P = 0.028; week 72: P = 0.025), and EZ disruption (week 72: P = 0.029; week 104: P = 0.019) were the clinical parameters most relevant to BCVA by univariate analysis in at least two time points. The mixed-effects model confirmed the relevance of intraretinal cyst vertical size (P = 0.001) and neovascularization (P = 0.001) but not EZ disruption (P = 0.119) over the course of the study.
Conclusions:
This study characterizes the course of visual loss in RR by identifying intraretinal cyst vertical size, neovascularization, and EZ disruption as biomarkers of poor BCVA over a span of two years. Larger multicenter studies are needed to confirm these findings.
[Ophthalmic Surg Lasers Imaging Retina 2024;55:255–262.]
Publisher
SLACK Incorporated,Slack, Inc,SLACK INCORPORATED
Subject
/ Angiogenesis Inhibitors - administration & dosage
/ Angiogenesis Inhibitors - therapeutic use
/ Atrophy
/ Cysts
/ Diabetes
/ Edema
/ Female
/ Humans
/ Ischemia
/ Male
/ Melanoma
/ Optical Coherence Tomography
/ Patients
/ Radiation Injuries - diagnosis
/ Radiation Injuries - drug therapy
/ Radiation Injuries - etiology
/ Ranibizumab - administration & dosage
/ Retina
/ Retinal Diseases - diagnosis
/ Retinal Diseases - drug therapy
/ Retinal Diseases - physiopathology
/ Tomography, Optical Coherence - methods
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
